Elizabeth Gerstner
Overview
Explore the profile of Elizabeth Gerstner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
2143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karschnia P, Arrillaga-Romany I, Eichler A, Forst D, Gerstner E, Jordan J, et al.
Neuro Oncol
. 2023 Jul;
25(12):2239-2249.
PMID: 37402650
Background: Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with central nervous system (CNS) involvement...
2.
Alvarez-Breckenridge C, Markson S, Stocking J, Nayyar N, Lastrapes M, Strickland M, et al.
Cancer Immunol Res
. 2022 Jun;
10(8):996-1012.
PMID: 35706413
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity...
3.
Griguer C, Oliva C, Coffey C, Cudkowicz M, Conwit R, Gudjonsdottir A, et al.
Neurooncol Adv
. 2022 Jan;
4(1):vdab186.
PMID: 35088051
Background: Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a...
4.
White M, Klein R, Shaw B, Kim A, Subramanian M, Mora J, et al.
JAMA Netw Open
. 2021 Aug;
4(8):e2120040.
PMID: 34369989
Importance: Leptomeningeal disease (LMD) is a devastating complication of cancer that is frequently underdiagnosed owing to the low sensitivity of cerebrospinal fluid (CSF) cytologic assessment, the current benchmark diagnostic method....
5.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M, et al.
Neuro Oncol
. 2020 Aug;
22(11):1706-1707.
PMID: 32823280
No abstract available.
6.
Ellingson B, Yao J, Raymond C, Nathanson D, Chakhoyan A, Simpson J, et al.
Clin Cancer Res
. 2020 Apr;
26(13):3135-3144.
PMID: 32269051
Purpose: GDC-0084 is an oral, brain-penetrant small-molecule inhibitor of PI3K and mTOR. Because these two targets alter tumor vascularity and metabolism, respectively, we hypothesized multiparametric MR-PET could be used to...
7.
Kaufmann T, Smits M, Boxerman J, Huang R, Barboriak D, Weller M, et al.
Neuro Oncol
. 2020 Feb;
22(6):757-772.
PMID: 32048719
A recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and...
8.
Wen P, Cloughesy T, Olivero A, Morrissey K, Wilson T, Lu X, et al.
Clin Cancer Res
. 2020 Jan;
26(8):1820-1828.
PMID: 31937616
Purpose: GDC-0084 is an oral, brain-penetrant small-molecule inhibitor of PI3K and mTOR. A first-in-human, phase I study was conducted in patients with recurrent high-grade glioma. Patients And Methods: GDC-0084 was...
9.
Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez G, Gerstner E, et al.
Neuro Oncol
. 2016 Jul;
18(11):1569-1578.
PMID: 27382115
Background: Gliomas with mutant isocitrate dehydrogenase (IDH) produce high levels of 2-hydroxyglutarate (2HG) that can be quantitatively measured by 3D magnetic resonance spectroscopic imaging (MRSI). Current glioma MRI primarily relies...
10.
Ellingson B, Bendszus M, Boxerman J, Barboriak D, Erickson B, Smits M, et al.
Neuro Oncol
. 2015 Aug;
17(9):1188-98.
PMID: 26250565
A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies,...